Biocartis Field Safety Notice

Biocartis Reference: BC-020351 Rev. 1

Date: December 15, 2022

BIOCARTIS

For Attention of: Laboratory Director

URGENT – Field Safety Notice

Idylla™ BRAF Mutation

Issue: False Positive Results

Product Name	Idylla™ BRAF Mutation Test
Device Identifier	
REF	A0010/6
UDI-DI (GTIN)	15415219111324
Production Identifier (Lot. No.)	Cartridge ID numbers 58450606 to 58450656 of lot 00005845
SW Version	N/A
Type of Action	Field Safety Corrective Action – Safety Alert

Dear Valued Customer,

Biocartis has identified a potential increased risk for false positive V600K/R/M results generated by the Idylla™ BRAF Mutation Test. This issue affects cartridge ID numbers 58450606 to 58450656 of lot 00005845 of the Idylla™ BRAF Mutation Test (Cat# A0010/6).

Description of situation

Biocartis received three complaints related to potential false positive Idylla™ BRAF Mutation Test runs. All three runs resulted in a 'MUTATION DETECTED IN BRAF CODON 600' with Mutation Type "V600K/V600R/V600M". Investigation of the amplification plots and Cq values revealed that all BRAF V600K/V600R/V600M curves had a sigmoidal shape. The ΔCq (the difference between the BRAF Wild Type Cq and the V600K/V600R/V600M Cq) showed a negative ΔCq, while in general a positive ΔCq value is expected. Retesting of the samples with another Idylla™ BRAF Mutation Test lot was performed, and all three samples returned a negative result for BRAF V600K/V600R/V600M.

Two cartridges, immediately following in sequence to the cartridges with discordant results, from the Idylla™ BRAF Mutation Test lot 00005845 were returned to Biocartis, and were tested with Wild Type FFPE slices (Horizon Discovery). Both runs also resulted in false positive BRAF V600K/V600R/V600M calls.

Biocartis immediately initiated an investigation of the event and identified a range of cartridges (ID

numbers 58450606 to 58450656) that could potentially generate a false positive call for V600K/V600R/V600M. Cartridges before or after this range are not impacted. Root cause investigation continues.

Potential risk

If a patient receives BRAF targeted therapy based on a false positive result (i.e., a test result with a V600K/V600R/V600M or a V600E/V600E2/V600D Mutation when the sample is truly a Wild Type), the patient will not respond to the therapy, which may lead to the following specific harms:

- Reduced chance of achieving an optimal treatment response
- Unnecessary exposure to the BRAF targeted therapy and related adverse effects.

If a patient receives immunotherapy, no harm to the patient is expected as immunotherapy is a therapy of choice for both BRAF Wild Type (WT) and BRAF V600 mutated melanoma.

Actions taken by Biocartis NV

- Biocartis has notified local Regulatory Authorities of this Field Safety Corrective Action.
- Biocartis shall continue the root cause investigation.

Actions to be taken by the customer user

Please review the test results obtained by using the Idylla™ BRAF Mutation Test lot 00005845. If any of the tests was performed with the impacted cartridges (ID numbers 58450606 to 58450656), the following actions should be taken:

- If test result was BRAF Wild Type or BRAF V600E/V600E2/V600D, no action is needed.
- If a V600K/V600R/V600M mutation was detected, please contact the oncologist to answer the questions in Appendix 1.

If you still have unused cartridges from lot 00005845 belonging to the impacted range (ID numbers 58450606 to 58450656), DO NOT use them. Contact your local Biocartis representative for further instructions.

Note that the Cartridge ID is located on the pouch label.

Communication of this Field Safety Notice

Forward this information to all individuals and departments within your organization that have received or used this product. If you are not the end user, please forward this notice to the device end user.

Please, maintain the awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action.

Completion of the acknowledgement of receipt

Due to regulatory reasons, completion of the Acknowledgement of Receipt (Appendix 1) is required for all recipients of this Field Safety Notice Please, complete and sign the attached Acknowledgement of Receipt form by **December 23, 2022**, and email to customersupport@biocartis.com.

The undersigned confirms that the appropriate Regulatory Agencies have been notified of this notice.

We sincerely apologize for any inconvenience this may cause and thank you in advance for your understanding and support.

If you need any further information or assistance concerning this notice, please contact Biocartis (email: customersupport@biocartis.com), or your local Biocartis representative.

Yours sincerely,

[redacted]

BIOCARTIS

URGENT – Field Safety Notice: Idylla™ BRAF Mutation Test

Appendix 1
Acknowledgement of Receipt

Please complete this form and return it by email to: customersupport@biocartis.com

1) We hereby confirm that:

- We have read and understood the Biocartis Field Safety Notice dated December 15, 2022, with reference BC-020351.
- We have taken the requested actions as mentioned in the Field Safety Notice.

Laboratory name:	
Address:	
Contact name:	Title:
Email address:	Phone number:
Provide: ID numbers of identified affected cartridge(s): ☐ I did not receive any cartridges of the affected range	
Results generated with the affected product(s) used for patient management: ☐ Yes - immunotherapy ☐ Yes – BRAF targeted therapy ☐ No	
Signature:	Date: